EU is poised to assist pharmaceutical firms in expanding the production of vaccines against Covid-19 to avoid "bottlenecks", according to the EU's Health and Food Safety Commissioner Stella Kyriakides by way of the French news agency AFP.
Kyriakides explains that potential delays in introducing approved vaccines to society owe to a lack of production capacity, and not to the lack of EU planning.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.